Breaking News

Parker Releases Unique Software Suite for Indego Exoskeleton

By Parker Hannifin Corporation | March 2, 2017

Indego is first exoskeleton to offer a non-trajectory based gait therapy concept.

The Human Motion and Control Business Unit of Parker Hannifin Corporation, the global leader in motion and control technologies, today announced the release of the Therapy+ Software Suite for its Indego exoskeleton in Europe. This sophisticated software suite is unique and makes Indego one of the most versatile exoskeletons for gait therapy.
 
“We are very proud to offer Indego and its Therapy+ Software Suite, as the first exoskeleton that allows non-trajectory based gait training in Europe”, said Achilleas Dorotheou, head of the human motion and control business unit for Parker. “Until today all commercially available exoskeletons moved patients on a pre-defined gait trajectory.”
 
Indego’s new control mechanism is based on proven motor learning principles and allows for an individualized, patient centric training approach where patients are in charge and the exoskeleton assists only when necessary. The facilitation of active patient participation during therapy is of critical importance for intense and efficient gait training. Additionally, this software offers auditory signals which provide real-time feedback to the patient and therapist to facilitate improved gait symmetry and mechanics.
 
Last week the Indego Therapy+ Software Suite was demonstrated for the first time in public during the International Stroke Conference in Houston, Texas. Clinicians from all over the world witnessed the smooth interaction between patient and device.
 
“I like how the device supports me when I need it but otherwise allows me to use and train my own leg muscles,” said Patti Wise, a participant in a large multi-center study with nine centers across the U.S., including six of the top 10 ranked rehabilitation centers.
 
This novel therapy offering is now available in Europe for neurological patients with gait impairments, and the goal of this trial is to collect safety-related data to obtain Food and Drug Administration (FDA) clearance later this year for Indego to gait train stroke patients in the U.S. as well.
 
“The non-trajectory based approach of Indego’s Therapy+ software offers a unique opportunity for gait training which hasn’t been previously been available in exoskeletons,” said Candy Tefertiller, Therapy Director at Craig Hospital in Englewood, CO, which is one of the nine study centers. “We are very excited and look forward to explore its fullest potential.”

Related News:

Related Markets:

Related Manufacturing: